Insights into glycan biosynthesis in chemically-induced hepatocellular carcinoma in rats: A glycomic analysis

Amr Amin, Asma Bashir, Nazar Zaki, Diane McCarthy, Sanjida Ahmed, Mohamed Lotfy

Abstract

AIM: To evaluate the qualitative and quantitative changes in N-linked glycosylation, which occurred in association with diethyl nitrosamine-induced hepatocellular carcinoma (HCC) in rodents.

METHODS: Liver tissues of (1) normal (non-tumor-bearing) rats; and (2) tumor-bearing rats; were collected and were used for histological and GlycanMap® analyses. Briefly, GlycanMap® analysis is a high-throughput assay that provides a structural and quantitative readout of protein-associated glycans using a unique, automated 96-well assay technology coupled to matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and custom bioinformatics. Histopathological studies were carried out to ensure the development of HCC in the tested animals.

RESULTS: The N-glycomic analysis revealed 5 glycans; GlcManGlcNAc2, GalManGlcNAcFuc Neu5, ManGlcNAc2, GalManGlcNAcNeu5OAc, and ManGlcNAcFuc, which showed significant changes in rat HCC tissues when compared with normal liver tissues. Four glycans were increased ($P < 0.05$) and GlcManGlcNAc was decreased ($5.89 \pm 0.45$ vs $3.54 \pm 0.21$, $P < 0.01$) in HCC tissues compared to normal tissues.
Glycosylation is an important post-transcriptional modification with over 50% of total proteins being glycosylated[1]. Glycosylation is crucial for cellular interaction; therefore, cancer involves noticeable changes in glycan biosynthesis. Thus, protein glycosylation (N- and O-glycosylation) is sensitive to environmental changes and is commonly disrupted in various diseases such as cancer[2-4]. Altered N-glycans and O-glycans may result from changes in the expression levels of glycan synthetic enzymes or from disruption of the biosynthetic pathway such as the ER-Golgi chain[5]. These changes can provide valuable insights into cancer development and its progression, and these altered glycosyl epitopes are classified as tumor-associated carbohydrate (TAC) antigens. Some of those TAC antigens are already in clinical use for the diagnosis and monitoring of cancers[6-9]. Recent technological advancements in the area of glycan isolation and characterization have turned glycomics into a new potential tool for cancer prognosis and treatment.

Since the beginning of the glycomics era, liver diseases such as fibrosis, cirrhosis and hepatocellular carcinoma (HCC) have been the prime targets in many investigations[10-13]. That trend was mainly driven by the lack of reliable diagnostic biomarkers of HCC. Many studies have shown that the serum N-glycan profile is a non-invasive marker for liver diseases such as HCC[12,14-17]. Serum N-linked glycoproteins are mainly produced in the liver and by B-lymphocytes, thus changes in the serum N-glycan profile reflect the physiology of liver and/or B-cells[12]. Various studies have shown significant changes in total N-glycan levels in the serum of HCC patients, thereby demonstrating the potential of glycans and glycome profiles as efficient biomarkers of HCC[12,19]. Alpha fetoprotein (AFP) is the only known biomarker used for HCC. AFP levels remain unchanged during the onset of HCC, which makes its application as a diagnostic marker for other liver diseases unreliable[20,21]. The glycosylated form of AFP, AFP-L3, was proposed as a new tumor marker and was approved by the FDA in 2006, for the early detection of primary HCC[22]. Studies also showed an increase in the fucosylated glycans in HCC patients compared to patients with chronic liver diseases[23,24]. However, there was no such increase in fucosylation in the liver tissues of HCC patients when compared with normal tissues, signifying the importance of glycan analyses in cancer tissues along with serum[25]. The serum profile of diethyl nitrosamine (DEN)-induced HCC has been investigated for new biomarkers[26]. The present study focuses on the analysis of N-glycan changes in DEN-induced HCC liver tissues. The glycan profiles of liver lysates from tumor-bearing rats and normal rats were analyzed using the Ezose GlycanMap® platform to identify changes in the N-glycans of liver tissues way to a HCC rodent model. Changes in N-glycan levels in the liver tissues could identify novel alterations in N-glycan profiles that are highly specific to HCC and its progression. A glycomic marker in rat livers may also be useful for screening drugs in this DEN-HCC rat model.

INTRODUCTION

Glycosylation is an important post-transcriptional modification with over 50% of total proteins being glycosylated[1]. Glycosylation is crucial for cellular interaction; therefore, cancer involves noticeable changes in glycan biosynthesis. Thus, protein glycosylation (N- and O-glycosylation) is sensitive to environmental changes and is commonly disrupted in various diseases such as cancer[2-4]. Altered N-glycans and O-glycans may result from changes in the expression levels of glycan synthetic enzymes or from disruption of the biosynthetic pathway such as the ER-Golgi chain[5]. These changes can provide valuable insights into cancer development and its progression, and these altered glycosyl epitopes are classified as tumor-associated carbohydrate (TAC) antigens. Some of those TAC antigens are already in clinical use for the diagnosis and monitoring of cancers[6-9]. Recent technological advancements in the area of glycan isolation and characterization turned glycomics into a new potential tool for cancer prognosis and treatment.

Since the beginning of the glycomics era, liver diseases such as fibrosis, cirrhosis and hepatocellular carcinoma (HCC) have been the prime targets in many investigations[10-13]. That trend was mainly driven by the lack of reliable diagnostic biomarkers of HCC. Many studies have shown that the serum N-glycan profile is a non-invasive marker for liver diseases such as HCC[12,14-17]. Serum N-linked glycoproteins are mainly produced in the liver and by B-lymphocytes, thus changes in the serum N-glycan profile reflect the physiology of liver and/or B-cells[12]. Various studies have shown significant changes in total N-glycan levels in the serum of HCC patients, thereby demonstrating the potential of glycans and glycome profiles as efficient biomarkers of HCC[12,19]. Alpha fetoprotein (AFP) is the only known biomarker used for HCC. AFP levels remain unchanged during the onset of HCC, which makes its application as a diagnostic marker for other liver diseases unreliable[20,21]. The glycosylated form of AFP, AFP-L3, was proposed as a new tumor marker and was approved by the FDA in 2006, for the early detection of primary HCC[22]. Studies also showed an increase in the fucosylated glycans in HCC patients compared to patients with chronic liver diseases[23,24]. However, there was no such increase in fucosylation in the liver tissues of HCC patients when compared with normal tissues, signifying the importance of glycan analyses in cancer tissues along with serum[25]. The serum profile of diethyl nitrosamine (DEN)-induced HCC has been investigated for new biomarkers[26]. The present study focuses on the analysis of N-glycan changes in DEN-induced HCC liver tissues. The glycan profiles of liver lysates from tumor-bearing rats and normal rats were analyzed using the Ezose GlycanMap® platform to identify changes in the N-glycans of liver tissues in a HCC rodent model. Changes in N-glycan levels in the liver tissues could identify novel alterations in N-glycan profiles that are highly specific to HCC and its progression. A glycomic marker in rat livers may also be useful for screening drugs in this DEN-HCC rat model.

MATERIALS AND METHODS

Animal care and use statement

Adult male albino rats, Wistar strain, (150-200 g) were obtained from the Animal House, UAE University, UAE.
They were maintained on a standard pellet diet and tap water ad libitum and were kept in polycarbonate cages with wood chip bedding under a 12 h light/dark cycle at room temperature (22 °C-24 °C). The rats were acclimatized to the environment for two-weeks prior to experimental use. This study was approved by the Animal Research Ethics Committee, UAE University.

**Hepatocarcinogenesis model**

Hepatocarcinogenesis was initiated by DEN and promoted by 2-Acetylaminofluorene (AAF) as described by Espandiari et al.[27] and modified by Amin et al.[28]. Briefly, as a mitotic proliferative stimuli, 4-d fasted rats were re-fed and the following day the rats were injected once intraperitoneally with DEN at 200 mg/kg b.wt., dissolved in saline. Two weeks post-DEN treatment, the rats received 6 daily intragastric doses of 2-AAF (30 mg/kg in 1% Tween 80) to promote liver cancer.

**Treatment regime**

The rats were divided into 2 groups (7 animals per group) as follows: Group 1 (normal): Rats were administered water at 5 mL/kg b.wt throughout the experimental period and were injected with one dose of saline. In Group 2 (tumor-bearing or HCC): Hepatocarcinogenesis was developed as detailed earlier. Group 1 was treated with an equal volume of vehicle. After 22 wk of DEN administration, all animals were anesthetized 24 h after the last treatment. Following anesthesia, liver samples were dissected out.

**Histology and immunohistochemistry**

Diethylether-anesthetized rats were sacrificed and the livers excised. Samples of the right, left and caudate liver lobes were immediately fixed in 10% buffered formalin for histopathological examination. The remaining liver was frozen in liquid nitrogen and stored at -80 °C. The rats were acclimatized to the environment for two weeks prior to experimental use. This study was approved by the Animal Research Ethics Committee, UAE University.

**Glycomic analysis**

Sample preparation: Liver tissue was collected from normal and tumor-bearing rats. The liver tissues were lysed in 50 mmol/L Tris-acetate, pH 7.4, containing 1% sodium dodecyl sulfate, 5 mmol/L EDTA, and 0.15 mmol/L NaCl followed by homogenization with a Polytron homogenizer. Homogenates were centrifuged to extract soluble materials, and 1/10 vol of 20% Triton X-100 was added. The extracts were dialyzed against 20 mmol/L ammonium bicarbonate for 48 h at 4 °C. After the dialysis, the recovered solution was lyophilized using a SpeedVac concentrator. Residual materials were reconstituted in 50 mmol/L ammonium bicarbonate and frozen until used.

**N-linked glycan isolation and purification:** The protein concentrations were normalized to 1 mg/mL and each sample was analyzed in duplicate to quantitate N-linked glycans using Ezose Sciences’ proprietary GlycanMap® methodology reported by Nishimura, Furukawa and Miura.[29-31] Aliquots of each sample were spiked with internal standards to aid quantification. The aliquots were denatured and then trypsinized, followed by heat-inactivation. The N-glycans were then enzymatically released from the peptides by treating with PNGase F (New England Biolabs) and the released glycans were subjected to solid-phase processing using chemo-selective beads. After being captured on the beads, the sialic acid residues were methyl esterified to stabilize them in the mass spectrometer. The glycans were simultaneously released from the beads and labeled, and aliquots of the recovered materials were spotted onto a MALDI target plate. Utilizing a fully automated, 96-well format, robotic technology, steps from initial aliquoting to spotting on the MALDI plate were performed.

**Mass spectrometric analysis:** MALDI-TOF MS analysis was performed on an Ultraflex III mass spectrometer (Bruker Daltonics) in the positive-ion, reflectron mode using a proprietary matrix composition. From the bead-based processing step, samples were spotted in quadruplicate, and spectra were obtained in an automated manner using the AutoXecute feature in flexControl software (Bruker Daltonics). Mass spectra were analyzed using Ezose’s proprietary bioinformatics programs (Figure 1A).

**Quantification using internal standard:** Raw mass spectra were smoothed and baseline subtracted.
prior to peak detection. Glycan compositions were assigned to each peak based on m/z. The intensities were normalized to that of an internal standard with known concentration. The normalized intensities from each of the quadruplicate spectra were averaged. Data were also corrected for the inherent decrease in peak intensity as m/z increases in mass spectrometric measurements, yielding absolute concentrations (in nmol/µg protein) that are equivalent to those created by HPLC/fluorescent glycan analysis methods. Glycan amounts were calculated by comparing peak heights to those of the internal standards. Glycan amounts were compared between treatment groups.

**Statistical analysis**
Data was analyzed by GraphPad Prism 6. Analysis of
The glycan flow was calculated by comparing the concentration of product glycan (Y) to the total concentration of product and substrate glycan (X + Y) as described above. An example of a glycomics analysis of an individual biosynthetic step in the mannose trimming pathways is shown below (Figure 2).

The statistical significance of differences in the glycan flow was evaluated using the Student t-test. Glycan changes that yielded P values < 0.05 in this analysis were considered significant. The statistical analysis was carried out by Asma Bashir from UAE University.

**RESULTS**

**DEN-induced foci of altered hepatocyte formation and GST-p expression**

HCC was induced by DEN-2AAF, and HCC induction in the rat model was verified by assessing serum AFP (data not shown) as reported previously [28]. The histological examination was carried out to assess HCC induction. Hepatic nodules were evident only in animals treated with DEN-2AAF, but not in normal rats (Figure 3). These nodules represent the classical foci of altered hepatocyte formation and are made up of big and irregularly shaped hepatocytes with large hyperchromatic nuclei. As induced GST-p is normally considered an early biomarker of hepatocarcinogenesis, GST-p foci larger than 15 cells were examined using a color image processor. The GST-p positive foci were significantly increased in animals treated with DEN-2AAF. Histological examination provided evidence of successful tumor development in DEN-induced HCC rats.

**Glycan analysis**

The Ezose Science proprietary GlycanMap® methodology (Figure 1A) was utilized to quantify N-linked glycans. This technique was previously developed by Nishimura, Furukawa and Miura [29-31]. Repeatability of the assay was evaluated using a standard human serum sample. Five aliquots of the standard were analyzed in parallel with the individual rat liver lysate samples and used to evaluate repeatability. Coefficients of variation (CVs) for individual glycans ranged from 7.5% to 24.8%, with a pooled CV of 14.8%. An overview of the N-glycan profile in rat liver is shown in Figure 1B. In total, 29 glycans were detected in our study, Figure 3A represents the overall profile of N-glycans analyzed. The glycan structure and the code used are shown in Figure 4.

**HCC is associated with glycan level changes**

Twenty nine glycans were detected and the changes in these glycans were analyzed. Glycans; Glc:Man:GlcNAc (code: 102000), Gal:Man:GlcNac:Fuc:Neu (code: 54110), Man:GlcNac (code: 42000), Gal:Man:GlcNac:NeuOAc (code: 54033), and Man:GlcNac:Fuc, (code: 35000) showed significant changes in rat HCC liver tissues when compared with normal liver tissues. Four were increased and one was decreased in HCC rats compared to normal rats (Figure 5).

**Differential effects of HCC on glycans**

The glycans detected can be classified into three categories including high mannose (simple mannose chains), hybrid (with fucosylation and sialylation) and complex (with complex branching structures) (Figure 6A). High mannose glycans, with the exception of Man® (Man®, Man®, Man® and Man®) were elevated (P < 0.05) in tumor-bearing rats compared to normal rats (Figure 6B). A non-significant decrease in fucosylated and sialylated glycans in HCC liver tissues was seen. However, a significant increase (P < 0.05) in sialyl-Lewis glycans (i.e., with fucose, galactose and sialyl groups) and O-acetylated glycans was seen in HCC liver tissues.

**Glycan fluctuations are correlated with their subcellular localization**

Analysis of core glycans based on the subcellular localization was performed using the Student t-test. Glycans; Glc:Man:GlcNAc (code: 102000), Gal:Man:GlcNac:Fuc:Neu (code: 54110), Man:GlcNac (code: 42000), Gal:Man:GlcNac:NeuOAc (code: 54033), and Man:GlcNac:Fuc, (code: 35000) showed significant changes in rat HCC liver tissues when compared with normal liver tissues. Although not all were significantly increased, the overall trend was a higher level in HCC tissues. The levels of glycans synthesized in medial-Golgi did not appear to follow a trend (Figure 7C).

**HCC alters the glycan flow**

To correlate the alterations in N-glycans with the enzymes involved in the biosynthetic pathway, the glycan flow was analyzed based on the ratio of adjacent glycans in the synthetic pathway. N-Glycans are synthesized from Glc:Man® in ER and Golgi via long chain glycosyltransferases (GT) and glycosylhydrolases (GH), and glycan flow is directly related to enzyme activity involved in these reactions [32]. In our study, the glycan flow was significantly decreased from Glc:Man® to Man® (P < 0.0005) (Figure 8A) explaining the increase in glycan Glc:Man® levels (Figure 5A). A
decrease ($P = 0.057$) in glycan flow in other mannose trimming reactions in the ER (from Man$_9$ to Man$_5$) was also observed. Glycan flow in cis-Golgi increased in HCC rats compared to normal rats with Man$_8$ to Man$_7$ flow increasing significantly ($P < 0.05$) (Figure 8B). The complex glycans synthesized in trans-Golgi showed an increase in flow from Man$_3$:GlcNac:Fuc$_1$:Neu$_2$ to Gal$_2$:Man$_3$:GlcNac$_4$:Fuc$_1$:Neu$_2$ in trans-Golgi (Figure 8D). This explains the increase in Gal$_2$:Man$_3$:GlcNac$_4$:Fuc$_1$:Neu$_2$ (Figure 5) in HCC liver tissues, which is an intermediate glycan in the reaction of Man$_3$:GlcNac$_4$:Fuc$_1$: to Gal$_2$:Man$_3$:GlcNac$_4$:Fuc$_1$:Neu$_2$.

DISCUSSION

Glycosylation is sensitive to microenvironment alterations and thus is involved directly in metastatic diseases such as cancer. These changes in glycosylation lead to the formation of tumor-specific glycans which are now believed to play an important role as biomarkers$^{[33,34]}$. The relatively high stability of glycans compared to other molecules (RNA and proteins) along with the development of new techniques such as MALDI-TOF and ESI profile have revolutionized the field of glycan research. Interestingly, aberrant glycosylation has been shown to develop before any changes in apoptosis and cell differentiation associated with cancer$^{[35]}$.

High mannose glycans have been shown to be prevalent in HCC liver tissues compared to normal liver tissues. One high mannose, Glc:Man:GlcNAc$_2$ was significantly elevated in HCC rats compared to normal rats in the present study (Figure 5). A similar increase in high mannose glycans was reported in other cancers$^{[36,37]}$. High mannose glycans have also been shown to increase in invasive and non-invasive breast cancer cells compared to normal epithelial cells$^{[36,37]}$. Another study showed up-regulation of high mannose oligosaccharides on cell surface glycoproteins in cancer cells compared to normal cells$^{[38]}$. N-linked glycans are constructed by a series of glycosyl transferases both in the ER and Golgi stacks. The chain starts with high mannose type glycans and then sequential mannose removal and addition of N-acetylgalactosamine and glucose residues leads to the formation of complex and hybrid glycans. Thus, high mannose glycans may be increased (accumulated) if either the mannose trimming enzyme is altered or downstream processing events are terminated or aberrated. ER mannosidase I (ERManI), an ER-based mannosidase, is responsible for a step-wise trimming of Man$_9$ to Man$_5$$^{[39]}$. ERManI expression has been shown to be aberrant in liver tissues of HCC patients and in hepatoma cells lines$^{[40]}$, which explains the increase in glycan Glc:Man:GlcNAc$_2$ (code: 102000) in the present study (Figure 5). Studies have shown that ERManI knockdown leads to accumulation of Man$_9$ and Gal:Man$_9$, and a decrease in Man$_5$ and Man$_6$.

Figure 3  Diethyl nitrosamine-induced increase of foci in altered hepatocytes and induction of GST-p expression in liver. Representative images of Hematoxylin and Eosin-stained liver sections from both studied groups: Normal (A), hepatocellular carcinoma (HCC) (B). Immunohistochemistry analysis of both normal (C) and HCC (D) livers labeled with GST-p are shown.

Amin A et al. Glycan profiling in induced-HCC liver
In liver cancer, induction of both $\alpha$-1,6- and $\alpha$-1,3-linked fucosylation has been reported as the most prominent serum N-glycosylation change associated with that disease\cite{41-43}. In the present investigation, fucosylated or sialylated glycans did not increase in HCC liver tissues compared to normal liver tissues, consistent with a study performed on human liver tissues of HCC patients\cite{25}. However, there was an increase in the relative abundance of sialyl Lewis glycans (fucose, galactose and NeuAc groups) in DEN-induced HCC. The sialyl-Lewis glycans are commonly

| Codes used | Glycan name       | Proposed structure |
|------------|-------------------|--------------------|
| 34000      | Man|GlcNAc |                |
| 34100      | Man|GlcNAc|Fuc |                |
| 35000      | Man|GlcNAc |                |
| 35100      | Man|GlcNAc|Fuc |                |
| 42000      | Man|GlcNAc |                |
| 43010      | Gal|Man|GlcNAc|Neu |                |
| 44010      | Gal|Man|GlcNAc|Neu |                |
| 44110      | Gal|Man|GlcNAc|Fuc |                |
| 45100      | Gal|Man|GlcNAc|Fuc |                |
| 52000      | Man|GlcNAc |                |
| 53010      | Gal|Man|GlcNAc|Neu |                |
| 54010      | Gal|Man|GlcNAc|Neu |                |
| 54020      | Gal|Man|GlcNAc|Neu |                |
| 54021      | Gal|Man|GlcNAc|Neu|OAc |                |
| 54030      | Gal|Man|GlcNAc|Neu |                |
| 54032      | Gal|Man|GlcNAc|Neu|OAc |                |
| 54033      | Gal|Man|GlcNAc|Neu|OAc |                |
| 54110      | Gal|Man|GlcNAc|Fuc|Neu |                |
| 54120      | Gal|Man|GlcNAc|Fuc|Neu |                |

Glycan compositions are expressed as a five-digit code, which represents the number of hexoses (Gal, Man, or Glc), N-acetylhexosamines (GlcNAc or GalNAc), deoxyhexoses (Fucose), N-acetylneuraminic (Neu5Ac) or O-acetates (OAc). Proposed glycan structures were assigned based on molecular weight and literature precedent.

Figure 4 This figure lists the glycan codes and proposed structures for all 29 glycans detected in this study.
abberated TAC in cancers\[^{44,45}\]. One such glycan, Gal-Man-GlcNac-Fuc-Neu (code: 54110) was increased in HCC rats compared to normal rats (Figure 5). TACs are expressed both by tumor and host cells and are involved in the key pathophysiological processes during the various steps of tumor progression, including tumor growth, cell migration, invasion, metastasis, angiogenesis, and evasion of innate immunity\[^{8,46-50}\]. TACs are studied extensively due to their potential as specific tumor biomarkers.

**Figure 5** Hepatocellular carcinoma-related alterations in glycans in tumor-bearing animals. Five glycans changed in tumor-bearing rats compared to normal rats. A combined scatter and box-and-whisker plot is shown for each glycan, along with an indication of the statistical significance \(P < 0.05\), \(P < 0.01\) vs control, \(n = 7\).

**Figure 6** Differential expression of N-glycans structures and determinants. A: N-Glycan structures i.e., high mannose, hybrid and complex; B: Distribution of the different types of high mannose structures (Man5 to Man9); C: Distribution of terminal glycan determinants: fucosylation, sialylation, sialyl-Lewis and O-acetylation. The groups were compared by t-test and \(P < 0.05\) vs control \(n = 7\).
Branched glycans are synthesized by adding antennae branching structures by glycotransferases (GnT) such as N-acetylglucosaminyltransferase V (GnT-V). GnT-V is the key enzyme that catalyzes the formation of 1,6 N-acetylglucosamine (GlcNAC) and adding it to a common core structure of Man:GlcNAC in the medial-Golgi apparatus. One product of this reaction is Man:GlcNAC (code: 35000), which was observed to be significantly increased in HCC rats compared to normal rats (Figure 5). Man:GlcNAC is a branched glycan synthesized from Man:GlcNAC by GnTs. Overexpression of GnTs is associated with metastasis and their implication in HCC have already been reported[51-53].

Siylation, the addition of sialic acid moieties, is an important modification of N-glycans that may alter the physical properties of molecules in the plasma membrane and may regulate immune cell function, as well as serve as specific ligands for certain toxins and lectins[54,55]. Sialic acids e.g., N-acetyllneuraminic acid (Neu5Ac) are capping structures on the glycans and may be further modified by various functional groups including acetyl, lactyl, methyl, sulfate, or phosphate groups. One such glycan, Gal:Man:GlcNac:Neu5AcOAc (54033) with three O-acetyl groups was shown to be significantly decreased in HCC rats compared to normal rats (Figure 4). Changes in the O-acetyl group are seen as irrelevant in terms of their role in disease prognosis. Recently, however, O-acetylated Neu5Ac has been shown to contribute to drug resistance in acute lymphoblastic leukemia cells and its removal made the cells vulnerable to cytotoxic drugs[56].

Subcellular localization and flow changes in N-linked glycans showed that the processing starts in the ER by sequential removal of glucose and mannose from Glc:Man:GlcNAC which continues in the Golgi complex. Mannose trimming is carried out by a series of mannosidases and extension is performed in Golgi by glycotransferases producing the complex-type and hybrid type. This study showed that changes in N-linked glycans followed a pattern depending on subcellular localization (Figure 7), which can be explained by the changes seen in glycan flow in the N-glycan biosynthesis pathway (Figure 8). An increase
| Glycan Flow Ratio | Normal | HCC |
|------------------|--------|-----|
| Glc:Man:GlcNac<sub>2</sub> | 1.05  | 1.00 |
| Man:GlcNac<sub>2</sub> | 0.95  | 0.90 |
| P | < 0.05 |

| Glycan Flow Ratio | Normal | HCC |
|------------------|--------|-----|
| Man:GlcNac<sub>2</sub> | 0.64  | 0.62 |
| Man:GlcNac<sub>2</sub> | 0.60  | 0.58 |
| P | 0.057 |

| Glycan Flow Ratio | Normal | HCC |
|------------------|--------|-----|
| Man:GlcNac<sub>2</sub> | 0.54  | 0.52 |
| Man:GlcNac<sub>2</sub> | 0.50  | 0.48 |
| P | < 0.05 |

| Glycan Flow Ratio | Normal | HCC |
|------------------|--------|-----|
| Man:GlcNac<sub>2</sub> | 0.45  | 0.40 |
| Man:GlcNac<sub>2</sub> | 0.40  | 0.35 |
| P | > 0.1 |

Amin A et al. Glycan profiling in induced-HCC liver
in high mannose glycans (Figure 6A) correlates with decreased glycan flow, showing significant ER stress in HCC liver tissues. An increase in sialyl-Lewis compared to fucosylated glycans (Figure 6C) can also be explained by the increased glycan flow in trans-Golgi which is the normal location for processing complex/hybrid glycans. The glycan levels may not give a clear indication of the disturbance in the synthesis pathway, but it is clearly depicted by glycan flow. The glycan flow clearly depicts the changes in enzymes involved in N-glycan biosynthesis.

In conclusion, we conducted a detailed analysis of N-glycans in HCC tissues compared to normal liver tissues. Five glycans were significantly altered. Together, the changes in glycan flow and subcellular localization provide an explanation for the increase in high mannose glycans and sialyl Lewis glycans reported in HCC tissues.

ACKNOWLEDGMENTS
Authors are grateful to Aktham Awad and Sayel Daoud (Tawam Hospital) for histology, Alaa Hamza (UAE University) for helping with the animals. Authors are also indebted to Youssef Abdalla (Groves High, MI, United States) for his technical assistance.

APPLICATIONS

Glycosylation is a fast-growing recent technology that has been utilized as a new potential tool for cancer prognosis and treatment. The lack of reliable diagnostic biomarkers has turned hepatocellular carcinoma (HCC) into the prime target of many glycomic-based analyses. Numerous investigations have shown significant changes in total N-glycan levels, including Alpha Fetoprotein (AFP), in the serum of HCC patients, thereby demonstrating the potential of glycans and the glycome profile as efficient biomarkers of HCC. As the only known biomarker used for HCC, levels of AFP remain unchanged during the onset of HCC, which makes its application as a differential diagnosis marker of other liver diseases unreliable. Although fucosylated glycans have been shown to increase in HCC patients compared to patients with chronic liver diseases, no such increase was reported in the liver tissues of HCC patients when compared with normal tissues. Therefore, glycan analyses of cancer tissues have become a priority.

In an attempt to utilize recent technology such as glycomics, the present study focuses on the analysis of the N-glycan changes in chemically-induced HCC liver tissues. Tissue glycan profiles were analyzed using the Ezoze GlycanMap® platform to identify changes in the N-glycans of liver tissues in a HCC rodent model.

Innovations and breakthroughs
The fact that defective glycosylation normally develops prior to any changes in apoptosis and cell differentiation associated with cancer has driven us to study how glycans are synthesized in HCC livers. This study showed a significant increase in the high mannose, Glc-Man-GlcNAc in HCC rats compared to normal rats. As the increase of such high mannose glycans may result from alterations in the mannose trimming enzyme, ER mannosidase I (ERManI), ERManI was also studied here. Similar to the livers of HCC patients, ERManI expression was shown to be aberrant as reflected in the increase in glycan Glc-Man-GlcNAc in the present study. TACs are studied extensively due to their potential as specific tumor biomarkers. Thus, as in different types of cancers, the sialyl-Lewis glycans (fucose, galactose and NeuAc groups) are commonly aberrated, the present study showed an increase in Gal-Man-GlcNAc-Fuc Neu in HCC rats compared to normal rats. This study also showed a significant decrease in acylated Gal-Man-GlcNAc-NeuOAc in HCC rats compared to normal rats. Recently, O-acetylated Neu5Ac (sialic acid) has been shown to contribute to drug resistance in acute lymphoblastic leukemia cells and its removal made the cells vulnerable to cytotoxic drugs. This investigation also showed a patterned change in N-linked glycans that depended on their subcellular localization. The increased high mannose glycans (decreased glycan flow) reflects a major ER stress in HCC tissues.

APPLICATIONS

The present detailed glycomic analysis of the N-glycans in HCC tissues

Figure 8 Glycan flow. Changes in glycan flow in the N-glycan biosynthesis pathway. The ratio was compared by t-test and P value < 0.05 was considered significant. A: ER; B: Cis-Golgi; C: Medial-Golgi; D: Trans-Golgi.
compared to normal liver tissues has led to a better understanding of how the changes in glycan flow and subcellular localization can provide an explanation of the increase in high mannose glycans and sialy Lewis glycans reported in HCC tissues. This may potentially lead to the identification of new and more reliable biomarkers of HCC.

**Terminology**

Liver cancer was chemically induced in rats. Liver tissues were collected from both cancer-induced and normal animals for further studies. An HCC-specific antigen (GST-p) was targeted with an antibody (Anti-GST-p) to confirm tumor formation. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis was performed and mass spectra were analyzed using Ezose’s proprietary bioinformatics programs. Glycan amounts were compared between the different animal groups.

**Peer-review**

These findings provide new index to diagnose the HCC, which has potential applications in clinic. This study did good work and used modern techniques to illustrate their conclusion. The authors have identified specific glycans from HCC tissue.

**REFERENCES**

1. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1999; 1473: 4-8 [PMID: 10580125]
2. Cazet A, Julien S, Bobowski M, Krzewinski-Rocchi MA, Hardain-Lepers A, Groux-Degrose A, Delannoy P. Consequences of the expression of sialylated antigens in breast cancer. Carbohydrate Res 2010; 345: 1377-1383 [PMID: 20251016 DOI: 10.1016/j.carres.2010.01.024]
3. Rachagni S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis and therapy of cancer. Biofactors 2009; 35: 509-527 [PMID: 19904814 DOI: 10.1002/biof.64]
4. Dube DH, Bertozzi CR. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4: 477-488 [PMID: 15931257 DOI: 10.1038/nrd1751]
5. Wopereis S, Lefebre DJ, Morava E, Wevers RA. Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin Chem 2006; 52: 574-600 [PMID: 16497938 DOI: 10.1373/clinchem.2005.063040]
6. Korekane H, Hasegawa T, Matsumoto A, Kinoshita N, Miyoshi E, Taniguchi N. Development of an antibody-lectin enzyme immunoassay for fucosylated α-fetoprotein. Biochim Biophys Acta 2012; 1820: 1405-1411 [PMID: 22233759 DOI: 10.1016/j.jbaigen.2011.12.015]
7. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingolipid metabolism. Cancer Res 1996; 56: 5309-5318 [PMID: 8968075]
8. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002; 99: 10231-10233 [PMID: 12149519 DOI: 10.1073/pnas.122708699]
9. Kannagi R, Iizawa M, Koike T, Miyazaki K, Kinamura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004; 95: 377-384 [PMID: 15132763]
10. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol 2009; 50: 592-603 [PMID: 19157620 DOI: 10.1016/j.jhep.2008.12.010]
11. Meaney DL. Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics 2011; 8 [PMID: 21906357 DOI: 10.1186/1559-0275-8-7]
12. Callewaert N, Van Vlierberghs H, Van Hecke A, Larow Y, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429-434 [PMID: 15152612]
13. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D’Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005; 43: 1007-1012 [PMID: 16137783 DOI: 10.1016/j.jhep.2005.05.028]
14. Vanderschaaghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequeencer-based serum glycomics. Mol Cell Proteomics 2009; 8: 986-994 [PMID: 19181625 DOI: 10.1074/mcp.M800470-MCP200]
15. Gui HL, Gao CF, Wang H, Liu YE, Xie Q, Dewaele S, Wang L, Zhuang H, Contreras R, Libert C, Chen B. Altered serum N-glycokies in chronic hepatitis B patients. Liver Int 2010; 30: 259-267 [PMID: 19951379 DOI: 10.1111/j.1477-3232.2009.02170.x]
Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Comunale MA, Proteome Res 2006; 5: 308-315 [PMID: 16457596 DOI: 10.1021/pr050328x]

Miyoshi E, Noda K, Yamaguchi Y, Inoue S, Ikeda Y, Wang W, Ko JH, Uozumi N, Li W, Taniguchi N. The alpha1-6-fucosyltransferase gene and its biological significance. Biochim Biophys Acta 1999; 1473: 9-20 [PMID: 10580126]

Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsuhashi Y, Irimura T. Increased expression of sialyl Lewis antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632-3637 [PMID: 8101764]

Pochechueva T, Jacob F, Fedier A, Heinzelmann-Schwarz V. Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Metabolites 2012; 2: 913-939 [PMID: 24957768 DOI: 10.3390/metabo2040913]

Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Exp Med Biol 2001; 491: 369-402 [PMID: 14533809]

Konska G, Guerry M, Caldefie-Chezet F, De Latour M, Guilhot J. Study of the expression of Tn antigen in different types of human breast cancer cells using VVA-B4 lectin. Oncol Rep 2006; 15: 305-310 [PMID: 16391846]

Goetz JA, Mecheff Y, Kang P, Jung MH, Novotny MV. Glycomic profiling of invasive and non-invasive breast cancer cells. Glyccon J 2009; 26: 117-131 [PMID: 18752066 DOI: 10.1007/s10719-008-9170-4]

de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto N, Groffen J. O-acetylated N-acetylneuraminic acid as a novel determinant in the cancer cell-surface glycanome. Glycobiology 2009; 19: 1056-1067 [PMID: 19528665 DOI: 10.1093/glycob/cwp085]

Ghazarian H, Idoni B, Oppenheimer SB. A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 2011; 113: 236-247 [PMID: 21998800 DOI: 10.1016/j.ahist.2010.02.004]

Hakomori S. Accelerating translational research by novel high-throughput approaches. Methods 2010; 11: 899-909 [PMID: 19433864 DOI: 10.1016/j.glyco.2009.06.009]

Foster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5: 526-542 [PMID: 16069816 DOI: 10.1038/nrc1649]

Jin XL, Liu HB, Zhang Y, Wang BS, Chen HL. Alteration in N-acetylgalactosaminyltransferase activities and glycoglycan structure in tissue and bile glycoproteins from extrahepatic bile duct carcinoma. Glycobiology 2009; 19: 899-909 [PMID: 19433864 DOI: 10.1016/j.glyco.2009.06.009]

D’Arrigo A, Belluco C, Ambrosi A, Digno M, Esposito G, Bertola A, Fabris M, Nofrato V, Mannmanno E, Leon A, Nitti D, Lisse M. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 2005; 115: 256-262 [PMID: 15688387 DOI: 10.1002/ijc.20883]

Mizuochi T, Nishimura R, Derappe C, Taniguchi T, Hamamoto T, Mochizuki M, Kobata A. Structures of the asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma. Appearance of triantennary sugar chains and unique biantennary sugar chains. J Biol Chem 1983; 258: 14126-14129 [PMID: 6643471]

Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 2007; 87: 851-857 [PMID: 17632542 DOI: 10.1038/landev.2007.65]

Schafer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009; 19: 507-514 [PMID: 19699080 DOI: 10.1016/j.csb.2009.06.003]

Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Mäschien M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. J Exp Med 2013; 210: 805-819 [PMID: 23478187 DOI: 10.1084/jem.20121482]

Amin A et al, Glycan profiling in induced-HCC liver
